Improved production of SARS-CoV-2 spike receptor-binding domain (RBD) for serology assays
Improved production of SARS-CoV-2 spike receptor-binding domain (RBD) for serology assays
Abstract The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein is a commonly used antigen for serology assays critical to determining the extent of SARS-CoV-2 exposure in the population. Different versions of the RBD protein have been developed and utilized in assays, with higher sensitivity attributed to particular forms of the protein. To improve the yield of these high-sensitivity forms of RBD and support the increased demand for this antigen in serology assays, we investigated several protein expression variables including DNA elements such as promoters and signal peptides, cell culture expression parameters, and purification processes. Through this investigation, we developed a simplified and robust purification strategy that consistently resulted in high levels of the high-sensitivity form of RBD and demonstrated that a carboxyterminal tag is responsible for the increased sensitivity in the ELISA. These improved reagents and processes produce high-quality proteins which are functional in serology assays and can be used to investigate seropositivity to SARS-CoV-2 infection. Highlights: Improved yields of SARS-CoV-2 spike RBD through modification of DNA constructs and purification parametersTwo versions of RBD show different sensitivity in serology assaysYields of greater than 50 mg/l obtained under optimal conditionsMagnetic bead purification technology improves throughput of protein production
Gillette William、Esposito Dominic、Mehalko Jennifer、Messing Simon、Taylor Troy、Denson John-Paul、Snead Kelly、Sadtler Kaitlyn、Drew Matthew、Wall Vanessa
Protein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, IncProtein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, IncProtein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, IncProtein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, IncProtein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, IncProtein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, IncProtein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, IncSection on Immuno-Engineering, National Institute for Biomedical Imaging and Bioengineering, National Institutes of HealthProtein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, IncProtein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc
生物科学研究方法、生物科学研究技术生物化学分子生物学
SARS-CoV-2COVID-19receptor-binding domainELISAserologyprotein production
Gillette William,Esposito Dominic,Mehalko Jennifer,Messing Simon,Taylor Troy,Denson John-Paul,Snead Kelly,Sadtler Kaitlyn,Drew Matthew,Wall Vanessa.Improved production of SARS-CoV-2 spike receptor-binding domain (RBD) for serology assays[EB/OL].(2025-03-28)[2025-06-12].https://www.biorxiv.org/content/10.1101/2020.11.18.388868.点此复制
评论